XLM price prediction shows potential recovery to $0.23 resistance after bouncing from $0.15 support, with RSI at oversold levels signaling possible reversal aheadXLM price prediction shows potential recovery to $0.23 resistance after bouncing from $0.15 support, with RSI at oversold levels signaling possible reversal ahead

XLM Price Prediction: Stellar Eyes $0.23 Recovery After Testing Key Support at $0.15

2026/02/10 15:07
4 min read

XLM Price Prediction: Stellar Eyes $0.23 Recovery After Testing Key Support at $0.15

Ted Hisokawa Feb 10, 2026 07:07

XLM price prediction shows potential recovery to $0.23 resistance after bouncing from $0.15 support, with RSI at oversold levels signaling possible reversal ahead.

XLM Price Prediction: Stellar Eyes $0.23 Recovery After Testing Key Support at $0.15

XLM Price Prediction Summary

Short-term target (1 week): $0.18-$0.19 • Medium-term forecast (1 month): $0.21-$0.23 range
Bullish breakout level: $0.23 (Upper Bollinger Band) • Critical support: $0.15

What Crypto Analysts Are Saying About Stellar

While specific analyst predictions are limited for the current period, Sin City Crypto (@SinCityCrypto1) provided a recent XLM chart analysis on February 4, 2026, focusing on price action patterns. However, no specific price targets were disclosed in their analysis.

According to on-chain data from major analytics platforms, Stellar's trading volume remains relatively stable at $6.99 million on Binance spot markets, suggesting maintained institutional interest despite the recent price decline. The lack of widespread analyst coverage may indicate XLM is currently undervalued relative to market attention.

XLM Technical Analysis Breakdown

Stellar's technical indicators present a mixed but increasingly bullish picture. The RSI at 31.06 sits in neutral territory but near oversold conditions, historically a favorable entry zone for XLM.

The MACD histogram at 0.0000 indicates bearish momentum is potentially exhausting, with the MACD line (-0.0160) and signal line (-0.0160) converging - often a precursor to trend reversal.

Bollinger Bands analysis reveals XLM trading at the 0.18 position between bands, closer to the lower band at $0.14 than the upper band at $0.23. This positioning typically suggests oversold conditions and potential mean reversion toward the middle band at $0.18.

Key moving averages show the challenge ahead: XLM trades below all major SMAs (7-day: $0.16, 20-day: $0.18, 50-day: $0.21, 200-day: $0.30), indicating a sustained downtrend that needs breaking for sustained recovery.

The Daily ATR of $0.01 suggests relatively low volatility, which could amplify any breakout moves once momentum shifts.

Stellar Price Targets: Bull vs Bear Case

Bullish Scenario

If XLM successfully holds the $0.15 strong support level, the Stellar forecast points to a recovery toward the 20-day SMA at $0.18, representing a 12.5% gain from current levels.

A break above $0.18 resistance would target the 50-day SMA at $0.21, while the ultimate bullish target sits at the upper Bollinger Band near $0.23 - a potential 44% upside move.

Technical confirmation would require RSI breaking above 40 and MACD histogram turning positive.

Bearish Scenario

Failure to hold $0.15 support could trigger further declines toward the lower Bollinger Band at $0.14, representing a 12.5% downside risk.

More concerning would be a break below $0.14, which could accelerate selling toward psychological support around $0.10-$0.12 levels.

Risk factors include continued crypto market weakness and lack of significant Stellar network developments to drive demand.

Should You Buy XLM? Entry Strategy

The current XLM price prediction suggests a strategic entry opportunity near $0.15-$0.156 support levels, with the asset trading close to oversold RSI conditions.

  • Primary entry: $0.155-$0.157 range
  • Stop-loss: $0.145 (below strong support)
  • Target 1: $0.18 (20-day SMA)
  • Target 2: $0.21 (50-day SMA)

Risk management should limit exposure to 2-3% of portfolio given the technical uncertainty and broader market conditions.

Conclusion

This XLM price prediction anticipates a potential 15-20% recovery over the next 2-4 weeks, contingent on holding current support levels. The combination of oversold RSI, converging MACD, and proximity to Bollinger Band support creates a cautiously optimistic Stellar forecast.

However, investors should remain vigilant of the broader crypto market sentiment and XLM's ability to reclaim key moving averages for sustained upward momentum.

Disclaimer: Cryptocurrency investments carry significant risk. This analysis is for informational purposes only and should not constitute financial advice. Always conduct your own research and consider your risk tolerance before investing.

Image source: Shutterstock
  • xlm price analysis
  • xlm price prediction
Market Opportunity
Stellar Logo
Stellar Price(XLM)
$0.1571
$0.1571$0.1571
-1.56%
USD
Stellar (XLM) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26